Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Open access
Narayan, Preeti, Prowell, Tatiana M., Gao, Jennifer J., Fernandes, Laura L., Li, Emily, Jiang, Xiling, Qiu, Junshan, Fan, Jianghong, Song, Pengfei, Yu, Jingyu, Zhang, Xinyuan, King-Kallimanis, Bellinda L., Chen, Wei, Ricks, Tiffany K., Gong, Yutao, Wang, Xing, Windsor, Katherine, Rhieu, Steve Y., Geiser, Gerlie, Banerjee, Anamitro, Chen, Xiaohong, Reyes Turcu, Francisca, Chatterjee, Deb K., Pathak, Anand, Seidman, Jeffrey, Ghosh, Soma, Philip, Reena, Goldberg, Kirsten B., Kluetz, Paul G., Tang, Shenghui, Amiri-Kordestani, Laleh, Theoret, Marc R., Pazdur, Richard, Beaver, Julia A. · 2021 · Clinical Cancer Research

Abstract

On May 24, 2019, the FDA granted regular approval to alpelisib in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, HER2-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. Approval was based on the SOLAR-1 study, a randomized, double-blind, placebo-controlled trial of alpelisib plus fulvestrant versus placebo plus fulvestrant. The primary endpoint was investigator-assessed progression-free survival (PFS) per RECIST v1.1 in the cohort of trial participants whose tumors had a PIK3CA mutation. The estimated median PFS by investigator assessment in the alpelisib plus fulvestrant arm was 11 months [95% confidence interval (CI), 7.5–14.5] compared with 5.7 months (95% CI, 3.7–7.4) in the placebo plus fulvestrant arm (HR, 0.65; 95% CI, 0.50–0.85; two-sided P = 0.001). The median overall survival was not yet reached for the alpelisib plus fulvestrant arm (95% CI, 28.1–NE) and was 26.9 months (95% CI, 21.9–NE) for the fulvestrant control arm. No PFS benefit was observed in trial participants whose tumors did not have a PIK3CA mutation (HR, 0.85; 95% CI, 0.58–1.25). The most common adverse reactions, including laboratory abnormalities, on the alpelisib plus fulvestrant arm were increased glucose, increased creatinine, diarrhea, rash, decreased lymphocyte count, increased gamma glutamyl transferase, nausea, increased alanine aminotransferase, fatigue, decreased hemoglobin, increased lipase, decreased appetite, stomatitis, vomiting, decreased weight, decreased calcium, decreased glucose, prolonged activated partial thromboplastin time, and alopecia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-3652

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 166

Metadata

Authors
Narayan, P., Prowell, T. M., Gao, J. J., Fernandes, L. L., Li, E., Jiang, X., Qiu, J., Fan, J., Song, P., Yu, J., Zhang, X., King-Kallimanis, B. L., Chen, W., Ricks, T. K., Gong, Y., Wang, X., Windsor, K., Rhieu, S. Y., Geiser, G., Banerjee, A., Chen, X., Reyes Turcu, F., Chatterjee, D. K., Pathak, A., Seidman, J., Ghosh, S., Philip, R., Goldberg, K. B., Kluetz, P. G., Tang, S., Amiri-Kordestani, L., Theoret, M. R., Pazdur, R., & Beaver, J. A.
Venue
Clinical Cancer Research
Published
2020-11-09
Volume
27
Issue
7
Pages
1842-1849
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3105871111
Cited by
166
References
2
FWCI
10.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-3652
The paper
Narayan, P., Prowell, T. M., Gao, J. J., Fernandes, L. L., Li, E., Jiang, X., Qiu, J., Fan, J., Song, P., Yu, J., Zhang, X., King-Kallimanis, B. L., Chen, W., Ricks, T. K., Gong, Y., Wang, X., Windsor, K., Rhieu, S. Y., Geiser, G., . . . Beaver, J. A. (2021). FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-3652

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.